{"id":"b1962","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, B1962 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"B1962 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:54.215Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06838546","phase":"PHASE2","title":"A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2025-02-24","conditions":"Advanced Colorectal Cancer","enrollment":80},{"nctId":"NCT06724263","phase":"PHASE2","title":"A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2024-12","conditions":"Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers","enrollment":120},{"nctId":"NCT05650385","phase":"PHASE1","title":"A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2022-12","conditions":"Neoplasms Malignant","enrollment":68}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["B1962 is a PD-L1/VEGF bispecific antibody fusion protein."],"phase":"phase_2","status":"active","brandName":"B1962","genericName":"B1962","companyName":"Tasly Biopharmaceuticals Co., Ltd.","companyId":"tasly-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"B1962 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}